Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
AssigneeCedars-Sinai Medical Center
InventorsHyung Kim, Yanping Wang
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.
Claims15
A method of treating a carcinoma or melanoma in a subject in need thereof, wherein the subject has been diagnosed with the carcinoma or melanoma, consisting essentially of:
- providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
- providing an anti-CD4 antibody or an antigen-binding fragment thereof;
- administering a therapeutically effective amount of the mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
- so as to treat the carcinoma or melanoma.
A method of inhibiting a carcinoma or melanoma in a subject in need thereof, consisting essentially of:
- providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
- providing an anti-CD4 antibody or an antigen-binding fragment thereof;
- administering a therapeutically effective amount of the mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
- so as to inhibit the carcinoma or melanoma.
A method of obtaining beneficial results in a subject with a carcinoma or melanoma, consisting essentially of:
- providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
- providing an anti-CD4 antibody or an antigen-binding fragment thereof;
- administering a therapeutically effective amount of the mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
- so as to obtain beneficial results in the subject.
A method of lessening or alleviating the severity of a carcinoma or melanoma in a subject, consisting essentially of:
- providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
- providing an anti-CD4 antibody or an antigen-binding fragment thereof;
- administering a therapeutically effective amount of the mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
- so as to lessen or alleviate the severity of the carcinoma or melanoma.
A method of slowing down a carcinoma or melanoma in a subject, consisting essentially of:
- providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
- providing an anti-CD4 antibody or an antigen-binding fragment thereof;
- administering a therapeutically effective amount of the mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
- so as to slow down a carcinoma or melanoma.
A method of reducing the tumor size of a carcinoma or melanoma in a subject, consisting essentially of:
- providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
- providing an anti-CD4 antibody or an antigen-binding fragment thereof;
- administering a therapeutically effective amount of the mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject, so as to reduce the tumor size of the carcinoma or melanoma.
Dependencies are inferred from the claim text.